Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PVLA vs DSGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PVLA Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 2–3 Matrix Metrics)
PVLA Overall Winner
6-Pillar Tally: PVLA 2 – 1 DSGN (3 Tie)
Matrix Metrics: PVLA 2 – 3 DSGN
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. PVLA 48.9/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
- Technical & Structure Timing Caution: PVLA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PVLA vs DSGN
PVLA
Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
$145.03
-4.89% 1D
Market Cap
$2.2B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.66β · 75% Vol
Unified Composite Score
48.9
HOLD
Tech 38.0
Fund 52.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
DSGN
Design Therapeutics, Inc. Common Stock
$9.94
-5.06% 1D
Market Cap
$677.5M
TTM Revenue
$33,000
Forward P/E
N/M
Beta / 30D Vol
1.32β · 61% Vol
Unified Composite Score
49.8
HOLD
Tech 55.0
Fund 57.0
Flow 63.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PVLA 2 – 1 DSGN)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
Tie
Revenue Growth (YoY)
+0.0%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$33,000
Market Cap
$2.2B
$677.5M
3. Profitability & Quality
DSGN
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-63.4%
-36.9%
4. Balance Sheet & Cash Flow
PVLA
Cash Generation (TTM)
-$43M
-$59M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$193M Net Cash
$13M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PVLA
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
47.9% (2nd %ile)
92.0% (13th %ile)
Put/Call OI Skew
3.82x (Put-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Distribution
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PVLA (2) vs DSGN (3)| Institutional Metric | PVLA | DSGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.2B | $677.5M | PVLA | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +0.0% | Tie | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -63.4% | -36.9% | DSGN | |
| 52-Week Range Position | 68% ($72–$180) | 30% ($7–$17) | PVLA | |
| Beta / 30D Volatility | 1.66β · 75% Vol | 1.32β · 61% Vol | DSGN | |
| Unified Institutional Score | 48.9 / 100 (HOLD) | 49.8 / 100 (HOLD) | DSGN | |
| Trailing 12M Revenue (USD) | N/A | $33,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$43M ($193M Net Cash) | -$59M ($13M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PVLA +24.15 pp
3M Horizon
PVLA +31.33 pp
6M Horizon
PVLA +45.16 pp
1Y Horizon
PVLA +39.37 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PVLA Revenue | DSGN Revenue | PVLA Op. Margin | DSGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2016 | $10M | N/A | -390.3% | N/A | PVLA |
| FY2017 | $30M | N/A | -57.7% | N/A | PVLA |
| FY2018 | $30M | N/A | -113.1% | N/A | PVLA |
| FY2019 | $40M | N/A | -62.2% | N/A | PVLA |
| FY2020 | $30M | $0M | -115.7% | -3685.8% | PVLA |
| FY2021 | $30M | N/A | -165.0% | N/A | PVLA |
| FY2022 | $30M | N/A | -167.8% | N/A | PVLA |
| FY2023 | $40M | N/A | -27.7% | N/A | PVLA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PVLA
CONSOLIDATION
Current IV
47.9%
IV Percentile
2nd %ile
Put/Call OI Skew
3.82x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DSGN
BREAKDOWN
Current IV
92.0%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PVLA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DSGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PVLA vs DSGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. PVLA 48.9/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PVLA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PVLA and DSGN split Growth & Scale metrics: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2016 to FY2023), PVLA cumulative revenue shifted +300.0% while DSGN shifted N/A. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.
PVLA and DSGN trade at balanced relative valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus DSGN (-36.9% ROE) capital efficiency.
In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DSGN vs PVLA · Reverse Pair
PVLA vs ORKA
· Sector Peer
PVLA vs DNTH
· Sector Peer
PVLA vs SYRE
· Sector Peer
DSGN vs CGEM
· Sector Peer
DSGN vs EWTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem